Revise termination related to prohibition on identification of 340B drugs

This bill (LC 2023) aimed to revise procedures for terminating a prohibition on identifying 340B drugs in healthcare settings. It would have affected hospitals and clinics participating in the federal 340B drug program, which provides discounted medications to eligible providers. The bill sought to change how the current rule preventing identification of 340B drugs could be ended. However, it died in process on May 22, 2025, and did not become law.